Exciting News for Our Leukemia Patients - Talha Badar @talhabadarmd.bsky.social oncodaily.com/voices/talha... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Key Abstracts to Watch in ALL at ASH 2025 - Talha Badar @talhabadarmd.bsky.social @ash.hematology.org oncodaily.com/voices/talha... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ALL #ASH25

Key Abstracts to Watch in MDS/CMML at ASH 2025 - Talha Badar @talhabadarmd.bsky.social oncodaily.com/voices/talha... #ASH2025 #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Promising cCR Rates in VICEROY Phase 1/2 FLT3m AML Study - Talha Badar @talhabadarmd.bsky.social oncodaily.com/voices/425957 #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Inside ASH25 with Talha Badar @ash.hematology.org @talhabadarmd.bsky.social oncodaily.com/voices/ash25... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ASH #ASH25 #ASH2025

👇🏽 Trial finding that led to approval: Menin inhibitor revumenib showed promising efficacy in R/R NPM1-mutated AML — CR + CRh = 23%, ORR ≈ 47%, median DOR ~ 4.7 mo, manageable QTc prolongation. 📈 Led to FDA approval (2025) for R/R NPM1m AML. #AML #Revumenib #MeninInhibitor doi.org/10.1182/blood.…

AML-defining cytogenetic and molecular abnormalities (regardless of blast count)between the WHO 5th Edition (2022) and the International Consensus Classification (ICC 2022). #leusm #MedTwitter #hemonctrainees #when_on_service 👇🏽

AML-defining cytogenetic and molecular abnormalities (regardless of blast count)between the WHO 5th Edition (2022) and the International Consensus Classification (ICC 2022). #leusm #MedTwitter #hemonctrainees #when_on_service 👇🏽

Olutasidenib alone or combined with azacitidine in pts with IDH1m MDS ashpublications.org/bloodadvances/… 👉🏾 PI/II data, Oluta show ORR (59%), CR ~27%, mDOR 14.6 mo & CR duration 20.5 mo; mOS 27.2 mo (n≈19) 👉🏾 cross-trial comparison; Ivo in MDS (image 2) ORR was 83% CR 39%, &mDOR NR, mOS 36 m#mdsds

Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML ashpublications.org/bloodadvances/… #Agile_study:mOSOS 24 mo.#cross-trialal comparison; VIALE-A trial mOS IDH2-m AML ( 27.5 vs 13 mo) & IDH1-m AML (median 10.2 vs 2.2 mo#leusms#AMLML

👇🏽 Trial finding that led to approval: Menin inhibitor revumenib showed promising efficacy in R/R NPM1-mutated AML — CR + CRh = 23%, ORR ≈ 47%, median DOR ~ 4.7 mo, manageable QTc prolongation. 📈 Led to FDA approval (2025) for R/R NPM1m AML. #AML #Revumenib #MeninInhibitor doi.org/10.1182/blood.…